Pharmaceutical Microbiology Manual
Download 1.15 Mb. Pdf ko'rish
|
ORA.007 Pharmaceutical Microbiology Manual
- Bu sahifa navigatsiya:
- Revised: 25 Aug 2020 Title: Pharmaceutical Microbiology Manual
F
OOD AND D RUG A DMINISTRATION O FFICE OF R EGULATORY A FFAIRS Office of Regulatory Science Document Number: ORA.007 Revision #: 02 Revised: 25 Aug 2020 Title: Pharmaceutical Microbiology Manual Page 82 of 92 For the most current and official copy, check QMiS. q. Adherence to an adequate Out of Specification (OOS) procedure which includes timely completion of the investigation r. Adequate reserve samples; documentation of reserve sample examination s. Stability testing program, including demonstration of stability indicating capability of the test methods (i.e. container/closure, AET) G. Sample Collection During an Establishment Inspection Samples of defective product constitute persuasive evidence that significant CGMP problems exist. Physical samples may be an integral part of a CGMP inspection where control deficiencies are observed. Physical samples should be correlated with observed control deficiencies. The investigator should consult Center and/or ORS Headquarters for guidance on quantity and type of samples (in-process or finished) to be collected. Documentary samples may be submitted when the documentation illustrates the deficiencies better than a physical sample. Divisions may elect to collect, but not analyze, physical samples, or to collect documentary samples to document CGMP deficiencies. Physical sample analysis is not necessary to document CGMP deficiencies. When a large number of products have been produced under deficient controls, collect physical and/or documentary samples of products which have the greatest therapeutic significance, narrow range of toxicity, or low dosage strength. Include samples of products of minimal therapeutic significance only when they illustrate highly significant deficiencies. H. Appendix A: Literature and Resources A Comprehensive List of Only Microbiological Regulatory and Scientific Literature Resources The scope of this reading material will ONLY include microbiological scientific and regulatory publications or websites for conventional drugs, biologics and combinatorial products. Some references to medical device regulations will be included if relevant during an FDA investigation that covers microbiology. 1. Legal requirements and regulations a. CFR 210 & 211 “cGMPs for finished Pharmaceuticals” b. CFR 210 & 211 amended effective Dec 2008 (several changes that include microbiological requirements of aseptically filled products) c. CFR 610 General Biological Product standards” (Not covered during this review) |
Ma'lumotlar bazasi mualliflik huquqi bilan himoyalangan ©fayllar.org 2024
ma'muriyatiga murojaat qiling
ma'muriyatiga murojaat qiling